Kyverna Therapeutics, Inc. expected to post a loss of 68 cents a share - Earnings Preview

Kyverna Therapeutics

07/08/2026 13:08

Kyverna Therapeutics, Inc. KYTX.OQ KYTX.O is expected to  show no change in quarterly revenue when it reports  results on August 10 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Kyverna Therapeutics, Inc. is for a loss of 68 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Kyverna Therapeutics, Inc. is $32.50, about 319.4% above its last closing price of $7.75
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.74
-0.75
-0.66
Beat
12.2
Dec. 31 2026
-0.70
-0.86
-0.80
Beat
6.8
Sep. 30 2025
-0.94
-0.97
-0.85
Beat
12.5​
Jun. 30 2025
-1.03
-1.04
-0.97
Beat
7
​​Mar. 31 2025
-1.18
-1.11
-1.03
Beat
7.5
Dec. 31 2024
-0.84
-0.88
Missed
-5​
Sep. 30 2024
-0.79
-0.79
-0.80
Missed
-1.5
Jun. 30 2024
-0.69
-0.70
-0.67
Beat
4
This summary was machine generated August 7 at 12:08 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)